BLINCYTO (blinatumomab), monoclonal antibody
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
Apr 06 2016
Reason for request
Inclusion
Moderate improvement in the treatment of Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia
- BLINCYTO has Marketing Authorisation in the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (Ph- B-ALL).
- Its efficacy in terms of complete remission (CR) and complete remission with partial haematological recovery (CRh) has been demonstrated. A little less than half of patients (40%) who achieved remission had received an allogeneic stem cell transplant.
- Clinical data are limited, pending the results of a comparative study.
- This is a second-line and subsequent treatment for Ph- B-ALL.
Clinical Benefit
Substantial |
- |
Clinical Added Value
moderate |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments